Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s (Alamy/PA) -

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said.

The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers.